Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the highest dose level of the study drug, 177Lu-PSMA-617
that can be given without severe side effects for advanced prostate cancer.